Phaseline

Targets › OXA

OXA: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout May 2029.

Open in Phaseline: the race on OXA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ivan Šitum, MDceftazidime/avibactam
Beta-lactam/beta-lactamase inhibitor - cephalosporin with avibactam inhibiting beta-lactam
SHV, OXA, KPCPhase 4Severe InfectionMay 2029

Conditions

Severe Infection (1)

Modalities

small molecule (1)

Companies

Ivan Šitum, MD (1)

Related targets

SHV (1) KPC (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.